Mangalam Organics reported a robust fiscal year for FY26, with net profit more than doubling to ₹25.38 crore, up 103.04% year-on-year. Revenue also grew by 17.46% to ₹622.57 crore. The company benefited from lower input costs and expansion in its B2C segment.
Profit for the year (PAT): ₹25.38 crore Revenue (FY26): ₹622.57 crore Reader Takeaway: Profitability boosted by cost efficiencies and B2C growth, with diversification efforts underway. ## What just happened Mangalam Organics Limited announced its financial results for the quarter and fiscal year ended March 31, 2026. For the full fiscal year 2026, the company reported a consolidated revenue from operations of ₹622.57 crore, a 17.46% increase compared to ₹530.01 crore in FY25. Profit After Tax (PAT) saw a significant jump of 103.04%, reaching ₹25.38 crore in FY26 from ₹12.50 crore in the previous year. EBITDA also grew by 49.91% to ₹87.82 crore. ## Why this matters This performance highlights the company's improved operational efficiency and profitability. The substantial PAT growth, outpacing revenue growth, suggests effective cost management and margin expansion. The company's strategic moves, including capacity expansion and B2C focus, are beginning to show positive results, indicating a move towards more diversified and potentially higher-margin revenue streams. ## The backstory Mangalam Organics has been working to reduce its dependence on the 'Camphor' market, which is considered a single-product market. The company has been investing in expanding its capacity for products like Bhimseni/Isoborneol flakes and growing its B2C segment, branded as CamPure. The recent capacity expansion for Bhimseni/Isoborneol flakes was completed in 2025. Management has emphasized a strategy to unlock the value of chemical intermediates. ## What changes now With the strong FY26 results, Mangalam Organics is demonstrating the success of its strategic initiatives. The B2C segment, Mangalam Brands Private Limited, showed a significant improvement in EBITDA margin, rising to 12.68% from 5.09% in FY25. This indicates a successful push into direct consumer markets. The company's focus on operational efficiencies and producing more sophisticated chemical intermediates suggests a path towards potentially more stable earnings and higher valuations. ## Risks to watch While the company is diversifying, its historical reliance on camphor remains a factor. Sustaining the high PAT growth and margin improvements will depend on managing input costs effectively and the continued success of its B2C expansion. Monitoring the progress in unlocking the value of intermediates is crucial for long-term growth. ## Peer comparison While direct comparisons for niche chemical intermediates and B2C expansions can be complex, the market generally rewards companies showing strong margin expansion and diversification away from commodity-like products. Companies in the specialty chemicals sector that demonstrate innovation and market penetration in B2C segments often see favorable investor sentiment. ## Context metrics (time-bound) * Revenue from operations in FY26 stood at ₹622.57 crore, up 17.46% from ₹530.01 crore in FY25. * Profit After Tax (PAT) for FY26 was ₹25.38 crore, a 103.04% increase from ₹12.50 crore in FY25. * EBITDA for FY26 was ₹87.82 crore, up 49.91% from ₹58.58 crore in FY25. * Earnings Per Share (EPS) for FY26 was ₹29.64, up 103.01% from ₹14.60 in FY25. * B2C segment EBITDA margin improved to 12.68% in FY26 from 5.09% in FY25. ## What to track next Investors will be looking for continued growth in the B2C segment, progress on the strategy to produce and sell more sophisticated chemical intermediates, and the ability to maintain improved profit margins in the face of potential input cost fluctuations.
Get stock alerts instantly on WhatsApp
Quarterly results, bulk deals, concall updates and major announcements delivered in real time.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.
